StockTitan

@stocktitan.net

2 weeks ago

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates CervoMed (NASDAQ: CRVO) reported positive Phase 2b RewinD-LB results and regulatory alignment for a planned Phase 3 in dementia with Lewy bodies (DLB).The company selected 50 mg TID neflamapimod for the Phase 3 (~300 patients) and expects multiple catalysts in H2 2026. Cash was $20.9M at year-end 2025 with an estimated ~six-month runway; full-year 2025 net loss was $27.0M.

#CRVO CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/CRVO/cervo-med-repo...

StockTitan

@stocktitan.net

3 weeks ago

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference CervoMed (NASDAQ: CRVO) will present Phase 2b RewinD-LB analyses at AD/PD 2026 in Copenhagen, March 17-21, 2026. Presentations include an oral talk on March 21 and a symposium on March 20.New secondary analyses by pre-specified plasma pTau181 and PK/PD data further support the planned Phase 3 dosing regimen and the chosen patient-enrichment cutoff for DLB patients without Alzheimer’s co-pathology.

#CRVO CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

www.stocktitan.net/news/CRVO/cervo-med-anno...

StockTitan

@stocktitan.net

1 month ago

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies CervoMed (NASDAQ: CRVO) completed a Phase 1 healthy volunteer study evaluating a new, stable crystal form of neflamapimod and selected 50 mg three times daily (TID) as the dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies (DLB).The company says the stable crystal form's pharmacokinetic profile largely overlaps with the clinically active DP Batch B from the Phase 2b extension; dose is increased to ensure target plasma concentrations are achieved.

#CRVO CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

www.stocktitan.net/news/CRVO/cervo-med-anno...

YesPunjab.com

@handle.invalid

1 month ago

Pakistan: Opposition holds protest outside SC, demands immediate hearings of cases against Imran Khan - Yes Punjab News PTI leaders protest outside Pakistan Supreme Court, demand hearings in Imran Khan cases and full medical check-up.

Pakistan: Opposition holds protest outside SC, demands immediate hearings of cases against Imran Khan yespunjab.com?p=220649

#ImranKhan #PTI #PakistanSupremeCourt #AdialaJail #ImranKhanHealth #CRVO #PakistanPolitics #BushraBibi #IslamabadNews #PTIProtest #GeoNews #DawnNews #AgencyNews

StockTitan

@stocktitan.net

4 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease

#CRVO CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

www.stocktitan.net/news/CRVO/cervo-med-anno...

StockTitan

@stocktitan.net

4 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB biomarker data on December 1, 2025 at CTAD showing neflamapimod reduced plasma GFAP, increased the Aβ42/40 ratio, and trended to lower NfL in dementia with Lewy bodies (DLB).Key controlled comparison used participants who received a higher-bioavailability capsule batch (DP Batch B) during a 32-week open-label extension versus their prior placebo period; GFAP change correlated with clinical CDR-SB change (r=0.35, p=0.036).

#CRVO CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

www.stocktitan.net/news/CRVO/cervo-med-pres...

StockTitan

@stocktitan.net

4 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference CervoMed (NASDAQ: CRVO) announced that neflamapimod will be featured in two presentations at the 18th CTAD conference, Dec 1–4, 2025 in San Diego.A late-breaking oral presentation on Dec 4, 2:10 p.m. PT will present full results from the Phase 2b RewinD-LB trial at 32 weeks, delivered by Prof. John-Paul Taylor. A poster (Poster 071) on Dec 1–2 reports that neflamapimod significantly lowers plasma GFAP and examines effects on NfL and Aβ42/40. Plasma assays were run at the Neurochemistry Laboratory, Amsterdam UMC under Prof. Charlotte Teunissen.

#CRVO CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

www.stocktitan.net/news/CRVO/cervo-med-to-s...

StockTitan

@stocktitan.net

4 months ago

#CRVO CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/CRVO/cervo-med-repo...

StockTitan

@stocktitan.net

5 months ago

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies CervoMed (NASDAQ: CRVO) announced written FDA feedback aligning on key elements of its planned global Phase 3 trial of neflamapimod for dementia with Lewy bodies (DLB).The company plans a single, randomized, double-blind, placebo-controlled Phase 3 in ~300 DLB patients, starting in the second half of 2026, with 32-week randomized treatment and a 48-week open-label extension. The primary endpoint is change in CDR-SB; participants with Alzheimer’s co-pathology will be excluded by imaging/CSF and a plasma ptau181 cutoff (≥21.0 pg/mL).

#CRVO CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

www.stocktitan.net/news/CRVO/cervo-med-anno...

Hartiful

@hartiful.bsky.social

5 months ago

I Had an Eye Stroke (CRVO) | My Health Update, Where have I been? YouTube video by Hartiful

I recently had a CRVO, eye stroke. I’ve just uploaded a YouTube video to try and help spread awareness ❤️

youtu.be/ajm9HuiSRdU?...

#crvo #eyestroke #healthjourney #awareness

StockTitan

@stocktitan.net

5 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies CervoMed (NASDAQ: CRVO) reported Phase 2b RewinD-LB results on Oct 8, 2025 showing neflamapimod activity in dementia with Lewy bodies (DLB).In participants with plasma ptau181 <21 pg/mL (low likelihood of Alzheimer’s co-pathology), NFMD/B produced significant within-subject improvement on CDR-SB versus placebo (difference = −1.12, p=0.005) and improved clinical scales during the first 16 weeks of the Extension Phase. NFMD/B reduced risk of clinically meaningful progression by 67% versus NFMD/A over 32 weeks and 75% versus placebo over 16 weeks (both p<0.001).Plasma GFAP fell with NFMD/B (median −16.7 pg/mL vs +5.8 pg/mL on placebo; median difference −23.1 pg/mL, p=0.016), and GFAP change correlated with CDR-SB change (p=0.036). The company expects FDA feedback on Phase 3 design in Q4 2025.

#CRVO CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

www.stocktitan.net/news/CRVO/cervo-med-anno...

StockTitan

@stocktitan.net

7 months ago

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates CervoMed (NASDAQ: CRVO) reported Q2 2025 financial results and provided updates on its Phase 2b RewinD-LB trial for neflamapimod in Dementia with Lewy Bodies (DLB). The 32-week Extension phase data showed a 54% risk reduction in clinical worsening, improving to 64% in patients with minimal Alzheimer's co-pathology.The company reported $33.5 million in cash and equivalents as of June 30, 2025, with funding runway into Q3 2026. Q2 2025 financial results showed grant revenue of $1.8 million, R&D expenses of $5.1 million, and a net loss of $6.3 million. CervoMed plans to engage with FDA in Q4 2025 to discuss Phase 3 trial design, with trial initiation targeted for mid-2026.The company also enrolled first patients in Phase 2a trials for acute stroke recovery and frontotemporal dementia.

#CRVO CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/CRVO/cervo-med-repo...

StockTitan

@stocktitan.net

8 months ago

Late-Breaking Phase 2b Results: CervoMed's Novel DLB Drug Shows Effects on Clinical Progression New clinical data reveals neflamapimod's impact on dementia with Lewy bodies progression. Late-breaking presentations at AAIC 2025 to showcase key findings. Get insights.

#CRVO CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

www.stocktitan.net/news/CRVO/cervo-med-anno...

StockTitan

@stocktitan.net

9 months ago

CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire Former Adipo CTO joins to lead neflamapimod manufacturing scale-up ahead of crucial Phase 3 DLB trial in 2026. See development timeline and strategic plans.

#CRVO CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

www.stocktitan.net/news/CRVO/cervo-med-anno...

StockTitan

@stocktitan.net

10 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates CervoMed (NASDAQ: CRVO) reported its Q1 2025 financial results and provided updates on its drug development programs. The company highlighted positive 16-week results from the extension phase of their Phase 2b RewinD-LB trial for neflamapimod in treating dementia with Lewy bodies (DLB). The trial showed significant improvements in clinical progression measures, with plans to initiate Phase 3 trials in mid-2026. The company ended Q1 with $35.2 million in cash, down from $38.9 million in December 2024. Financial results showed grant revenue of $1.9 million, R&D expenses of $4.8 million (up from $2.8 million), and a net loss of $4.9 million (increased from $2.5 million). CervoMed is also expanding its drug development pipeline with new Phase 2a trials for primary progressive aphasia and ischemic stroke recovery.

#CRVO CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/CRVO/cervo-med-repo...

StockTitan

@stocktitan.net

1 year ago

New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference Latest Phase 2b trial results for neflamapimod in Lewy body dementia to be presented by CEO and Harvard researcher. Key efficacy insights coming April 2025.

#CRVO CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

www.stocktitan.net/news/CRVO/cervo-med-anno...

Profit Trading USA

@profittradingusa.bsky.social

1 year ago

Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Yahoo Finance Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?  Yahoo Finance

Click Subscribe #CervoMed #CRVO #ShortSqueeze #StockMarket #Investing

StockTitan

@stocktitan.net

1 year ago

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates CervoMed (NASDAQ: CRVO) has reported its Q4 and full-year 2024 financial results, highlighting positive 16-week results from the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). The trial showed significant improvements in the primary outcome measure.Financial highlights include:Cash position of $38.9 million as of December 31, 2024 (up from $7.8M in 2023)Grant revenue of $9.7 million for 2024 (up from $7.1M in 2023)R&D expenses increased to $18.8 million (from $8.4M in 2023)Net loss of $16.3 million for 2024The company plans to initiate a Phase 3 trial in mid-2026 and expects to report 32-week extension phase results in H2 2025. Current cash runway extends into mid-2026.

#CRVO CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/CRVO/cervo-med-repo...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Most searched small-cap stocks, Thu Mar 13th - #BTE #HMR #WOLF #UUUU #UEC #SMR #RGTI #QBTS #NXE #APLD #CRVO #IQ #RGC #HL #QUBT #WULF #BBAI #FSM #TGB #JBLU - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Most searched small-cap stocks, Wed Mar 12th - #TGB #CORZ #GV #IQ #JBLU #VRN #RIG #IRBT #FUBO #UUUU #LUNR #TLYS #SSRM #RGTI #QBTS #NVAX #LPG #FOSL #CRVO #BTCS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks with improving money flow, Tue Mar 11th - #UFCS #ZVRA #RGR #TSVT #SLRN #RANI #QURE #PFC #MMLP #INBX #CRVO #BLTE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies CervoMed (NASDAQ: CRVO) has announced positive results from the 16-week extension phase of its Phase 2b RewinD-LB study for neflamapimod in treating dementia with Lewy bodies (DLB). The new batch of drug capsules showed significant improvements compared to both old capsules and placebo:Key findings include:Improved Clinical Dementia Rating Sum of Boxes (CDR-SB) scores (pBetter performance on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (p=0.035)Lower incidence of falls (7.4% vs. 14.5% for old capsules)Higher plasma drug concentrations (5.1 vs. 4.0 ng/mL, p=0.03)The study involved 149 participants, with 94 receiving the new capsules and 55 receiving old capsules. The results suggest neflamapimod's potential to fundamentally change DLB treatment, particularly significant as no FDA-approved drugs currently exist for DLB management in the U.S.

#CRVO CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

www.stocktitan.net/news/CRVO/cervo-med-anno...

StockTitan

@stocktitan.net

1 year ago

Clinical Trial Setback: CervoMed's Dementia Drug Gets Second Chance with Enhanced Formula CervoMed's neflamapimod fails to outperform placebo in Phase 2b DLB trial, but new capsule formulation achieves target plasma levels. Key efficacy data expected Q1 2025.

#CRVO CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

www.stocktitan.net/news/CRVO/cervo-med-prov...

Yolo

@yolo-tdm.bsky.social

1 year ago

a group of women are standing around a mannequin with the words it 's on sale ALT: a group of women are standing around a mannequin with the words it 's on sale

#CRVO

StockTitan

@stocktitan.net

1 year ago

CervoMed's Dementia Drug Trial Falls Short as Key Phase 2b Study Misses Primary Endpoints CervoMed's neflamapimod trial for dementia with Lewy bodies fails to achieve statistical significance, leading to Phase 3 preparations being paused pending further analysis.

#CRVO CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

#clinicaltrial #investing #news

www.stocktitan.net/news/CRVO/cervo-med-anno...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #CRVO ) CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

#StockMarket #News